Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Share-based Compensation (2016 - 2025)

KalVista Pharmaceuticals' Share-based Compensation history spans 10 years, with the latest figure at $3.6 million for Q2 2025.

  • For Q2 2025, Share-based Compensation fell 71.42% year-over-year to $3.6 million; the TTM value through Apr 2025 reached $22.4 million, up 2.32%, while the annual FY2025 figure was $12.3 million, 43.92% down from the prior year.
  • Share-based Compensation for Q2 2025 was $3.6 million at KalVista Pharmaceuticals, up from $3.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.7 million in Q2 2024 and bottomed at $2.7 million in Q1 2024.
  • The 3-year median for Share-based Compensation is $3.2 million (2023), against an average of $4.5 million.
  • The largest annual shift saw Share-based Compensation dropped 6.49% in 2024 before it plummeted 71.42% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $3.2 million in 2023, then fell by 6.49% to $3.0 million in 2024, then rose by 21.44% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Share-based Compensation are $3.6 million (Q2 2025), $3.0 million (Q4 2024), and $3.0 million (Q3 2024).